|This activity is available for free to members of NASP. Visit the top section of www.ProCE.com/CSPE for details.|
A product of the National Association of Specialty Pharmacy's (NASP) Center for Specialty Pharmacy Education(CSPE). View more NASP/CSPE Activities
This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.
Ovarian cancer is the fifth most frequent cause of cancer death in women. It is imperative that pharmacists and nurses are aware of the therapeutic options for the management of ovarian cancer including the novel poly (ADP-ribose) polymerase inhibitors (PARP inhibitors). This session will cover the mechanism of action of the PARP inhibitors and the efficacy and safety parameters of the ovarian cancer treatment options available.
The target audience for this activity includes pharmacists and nurses.
Upon completion of this activity, participants will be able to:
- Describe the epidemiology, risk factors, and pathology of ovarian cancer.
- Outline the efficacy and safety of available treatment options for ovarian cancer.
- Develop individualized management plans for patients with ovarian cancer involving the selection of optimal treatment strategies.
- Formulate approaches to managing patients with ovarian cancer receiving treatment.
Megan May, PharmD, BCOP
Clinical Oncology Pharmacy Specialist
Baptist Health Lexington
Release Date: June 30, 2021
Expiration Date: June 30, 2024
ACPE Credit Designation (Pharmacist CE)
This CE activity is jointly provided by ProCE, LLC and the National Association of Specialty Pharmacy (NASP). ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-21-148-H01-P has been assigned to this home study knowledge-based activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. Completion of an evaluation and post-test with a score of 70% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by ProCE, LLC and Clinical Care Options, LLC (CCO). Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.
It is the policy of ProCE, LLC to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation.
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty and planners reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Megan May has no relevant conflicts of interest to report.
CCO and ProCE Staff have no relevant conflicts of interest to report.
Gabriela Ziccarelli does not have any relevant conflicts of interest to report.
Robin Wanous-Williamson (nurse planner) has no relevant conflicts of interest to report.
Potential conflicts of interest were resolved with a peer review process provided by Gabriela Ziccarelli, PharmD.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is self-funded by NASP.
|Activity Number||Credit Amount||Accreditation Period|
|0221-9999-21-148-H01-P||1 Contact Hour||June 30, 2021 - June 30, 2024|
|CCO-Nurses (1299)||1 Credit||June 30, 2021 - June 30, 2024|